Festivals and fairs plan summer comeback
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new drug could be a blockbuster
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Farmers, water agencies brace for drought
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
‘A big change’ on the way as some companies continue remote work
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Cal Poly study: Morro Bay wind power could bring thousands of jobs
A wind farm off the coast of Morro Bay could bring 650 jobs and $262 million in annual economic impact to the Central Coast, and an onshore port to assemble and service wind turbines would be a much bigger economic boost, according to a new study by researchers from Cal Poly San Luis Obispo. The Read More →
Register now for our Best Places to Work awards reception and panel discussion
What makes a great place to work on the Central Coast? The Pacific Coast Business Times 2021 Central Coast Best Places to Work virtual luncheon will take place June 24 at 1 p.m. Join us as we recognize top employers in Ventura, Santa Barbara and San Luis Obispo counties. After collecting more than 1,000 nominations through an employee-based survey, Read More →
Amgen gets FDA approval for potential billion-dollar drug
Thousand Oaks-based Amgen won approval from the U.S. Food and Drug Administration on May 28 for its latest oral drug treatment, Lumakras, potentially adding another huge market for one of the largest biotech firms in the world. According to the Wall Street Journal, Amgen will charge $17,900 a month for the drug and analyst think Read More →
